SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/12 – ‘EX-13.B’

On:  Friday, 3/15/13, at 10:36am ET   ·   For:  12/31/12   ·   Accession #:  1176256-13-165   ·   File #:  1-12033

Previous ‘20-F’:  ‘20-F’ on 3/15/12 for 12/31/11   ·   Next:  ‘20-F’ on 3/14/14 for 12/31/13   ·   Latest:  ‘20-F’ on 5/2/23 for 12/31/22   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/15/13  Nymox Pharmaceutical Corp         20-F       12/31/12    6:1.1M                                   e3 Fil… Computershare/FA

Annual Report by a Foreign Private Issuer   —   Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report for the Fiscal Year Ended December    HTML    833K 
                          31, 2012                                               
 2: EX-4.V      Common Stock Private Purchase Agreement Dated       HTML    106K 
                          November 1, 2012                                       
 5: EX-13.A     Sox Section 906 CEO Certification                   HTML      6K 
 6: EX-13.B     Sox Section 906 CFO Certification                   HTML      6K 
 3: EX-12.A     Sox Section 302 CEO Certification                   HTML     10K 
 4: EX-12.B     Sox Section 302 CFO Certification                   HTML     10K 


EX-13.B   —   Sox Section 906 CFO Certification


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Exhibit 13(b)  

Exhibit 13 (b)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Roy Wolvin, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report on Form 20-F for the year ended December 31, 2012 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Nymox Pharmaceutical Corporation.

Date: March 15, 2013

/s/ Roy Wolvin
Roy Wolvin
Chief Financial Officer
Nymox Pharmaceutical Corporation




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘20-F’ Filing    Date    Other Filings
Filed on:3/15/136-K
For Period End:12/31/126-K
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/15/13  SEC                               UPLOAD9/27/17    1:36K  Nymox Pharmaceutical Corp.
 8/06/13  SEC                               UPLOAD9/27/17    1:154K Nymox Pharmaceutical Corp.
 7/24/13  SEC                               UPLOAD9/27/17    1:152K Nymox Pharmaceutical Corp.
 7/05/13  SEC                               UPLOAD9/27/17    1:155K Nymox Pharmaceutical Corp.
Top
Filing Submission 0001176256-13-000165   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 3:46:05.1pm ET